Under the deal, AstraZeneca received an exclusive license for the development of bispecific and multispecific antibody products based on one of Compugen's pipeline programs.

Compugen received a $10 million upfront payment and is eligible to receive up to $200 million in development, regulatory, and commercial milestones for the first product, as well as tiered royalties on future product sales, the company said.

Inovio to develop COVID-19 DNA-encoded monoclonal antibodies
Inovio, along with a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, has received a...

AstraZeneca to test Russian Sputnik V vaccine
AstraZeneca said it will use one of the components of the Sputnik V vaccine, Russia's COVID-19 vaccine, in its own clinical trials for a COVID-19 vaccine....

AstraZeneca, Qure.ai partner for lung cancer diagnosis
AstraZeneca has partnered with deep-learning algorithm developer Qure.ai to integrate artificial intelligence solutions for the early detection of lung...

AstraZeneca COVID-19 vaccine achieves 70% efficacy
AstraZeneca released interim analysis from clinical trials of AZD1222, its COVID-19 vaccine candidate in the U.K. and Brazil, with data demonstrating...

Oxford/AstraZeneca COVID-19 vaccine strongly efficacious in older adults
Similar safety and immunogenicity profiles were observed in adults and older adults who received the Oxford/AstraZeneca SARS-CoV-2 vaccine candidate,...